Pharma News

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APVO-436 overview

APVO-436 is under development for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome. It is a bi-specific antibody. It acts by targeting CD123 and CD3. The drug candidate is administered through intravenous route. It is developed based on the ADAPTIR and OmniAb platform technology. It was also under development for the treatment of acute lymphocytic leukemia and hairy cell leukemia.

Aptevo Therapeutics overview

Aptevo Therapeutics (Aptevo) is a clinical-stage biotechnology company that develops and commercializes oncology and hematology therapeutics. Its pipeline products include APVO436 for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); ALG.APV-527 for potential treatment of a broad spectrum of cancers including mesothelioma, cervical, prostate, renal, breast, non-small-cell-lung, gastric, colorectal and bladder cancers; APVO603 for solid tumors. Aptevo has received Orphan Drug Designation (ODD) for its pipeline product APVO436 from the US FDA for the treatment of acute myelogenous leukemia (AML). The pipeline immuno-oncology candidates are built on its proprietary Adaptir and Adaptir-Flex platform technologies. Aptevo is headquartered in Seattle, Washington, the US.

For a complete picture of APVO-436’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 August 2023

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.



Source link
#APVO436 #Aptevo #Therapeutics #Myelodysplastic #Syndrome #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *